Priya Singhal Sells 2,660 Shares of Biogen (NASDAQ:BIIB) Stock

10 Feb 2026, 20:48 by Scott Moore · The Cerbat Gem

Biogen Inc. (NASDAQ:BIIB – Get Free Report) insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Priya Singhal also recently made the following trade(s):

On Monday, February 2nd, Priya Singhal sold 748 shares of Biogen stock. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40.

Biogen Stock Down 2.5%

NASDAQ BIIB traded down $4.82 during midday trading on Tuesday, hitting $188.99. 1,836,099 shares of the company traded hands, compared to its average volume of 1,646,308. The company has a market cap of $27.74 billion, a PE ratio of 21.45, a price-to-earnings-growth ratio of 1.55 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $202.41. The company’s 50-day simple moving average is $177.44 and its 200-day simple moving average is $157.89.

Biogen (NASDAQ:BIIB – Get Free Report) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter last year, the company earned $3.44 earnings per share. The firm’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Truist Financial increased their price objective on shares of Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a research report on Monday. Sanford C. Bernstein reissued a “market perform” rating on shares of Biogen in a report on Monday. Wells Fargo & Company raised their target price on Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Sunday. Oppenheimer boosted their price target on Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, January 30th. Finally, Tudor Pickering set a $201.00 price objective on Biogen in a report on Monday. Thirteen investment analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $206.21.

View Our Latest Research Report on Biogen

Hedge Funds Weigh In On Biogen

A number of institutional investors have recently modified their holdings of BIIB. Vanguard Group Inc. boosted its stake in shares of Biogen by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after buying an additional 157,857 shares during the last quarter. State Street Corp lifted its holdings in Biogen by 1.0% in the second quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock valued at $938,007,000 after acquiring an additional 71,897 shares during the period. Geode Capital Management LLC boosted its position in Biogen by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after purchasing an additional 130,618 shares in the last quarter. Norges Bank acquired a new stake in shares of Biogen during the 4th quarter worth approximately $464,408,000. Finally, Invesco Ltd. grew its stake in shares of Biogen by 4.2% during the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after purchasing an additional 98,001 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

Positive Sentiment: Q4 beat and updated guidance — Biogen reported Q4 results and FY guidance that topped expectations (EPS and revenue beats; FY2026 EPS range of 15.25–16.25), a key driver for recent analyst upgrades and higher targets. Article Title
Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The biologics license application for a subcutaneous formulation of Leqembi (lecanemab) was designated for priority review, which could materially expand the Alzheimer’s franchise if approved. Article Title
Positive Sentiment: Multiple bullish analyst moves lift upside — Several firms raised price targets and/or maintained Buy ratings after the results and pipeline updates (Goldman Sachs PT raised to $231; RBC to $233; HC Wainwright to $228; Canaccord and others also raised targets), supporting multi-quarter upside expectations. Article Title
Neutral Sentiment: Pipeline diversification headlines (lupus, SMA) — Management and coverage note advancing programs beyond Alzheimer’s, which improves long-term growth optionality but will take time to materialize. Article Title
Neutral Sentiment: Mixed analyst stances — Several shops raised price targets but kept neutral/hold ratings (Citigroup, Piper Sandler, Wedbush, Truist), indicating disagreement on valuation even after beats. Article Title
Neutral Sentiment: Short-interest report appears unreliable — A reported “significant increase” shows zero shares in the feed (data inconsistent); no clear short-covering pressure signaled. (internal short-interest entry)
Negative Sentiment: Ongoing franchise pressure and execution risk — Coverage notes that legacy multiple sclerosis (MS) franchise pressures and execution on expanding Leqembi access/commercial scale remain risks that could cap near-term upside. Article Title

Biogen Company Profile

(Get Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.